QuANTUM-First: FLT3-ITD-specific MRD to assess benefits of quizartinib in FLT3-ITD+ AML

Alexander Perl, MD, University of Pennsylvania, Philadelphia, PA, gives an overview of data from further analyses of the Phase III QuANTUM-First study (NCT02668653), which evaluated the FLT3 inhibitor quizartinib in patients with newly diagnosed FLT3-ITD+ acute myeloid leukemia (AML). Initial results of the trial demonstrated that quizartinib, added to intensive induction and consolidation with or without transplant and followed by single-agent continuation therapy, significantly improved overall survival (OS). This analysis evaluated if FLT3-ITD-specific measurable residual disease (MRD) in the patients of the study cohort impacted the clinical outcome or the benefits provided by quizartinib. Dr Perl highlights that the data demonstrated the potential prognostic utility of FLT3-ITD-specific MRD measurements and that long-term OS benefits conferred by quizartinib may partly derive from a deep and sustained reduction of the FLT3-ITD+ leukemia burden. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.